COMPANY RESEARCHCo-commercializes approved LINZESS and holds regional rights, alongside oral peptide discovery through Nimble. ABBV-859 is in Phase 1; its exact structure and mapping to Nimble assets remain unconfirmed.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
AbbVie completed its acquisition of Nimble in 2025, adding an oral IL23R peptide and synthesis / screening platform. The program was preclinical at the time of that announcement.
Add approved linaclotide commercial roles and a separately labeled ABBV-859 Phase 1 fact; do not infer exact ring structure or asset identity from secondary databases alone.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| Nimble oral IL23R peptide | IL-23R · Psoriasis | Preclinical（历史） | Quantitative human results not confirmed in this review |
| linaclotide / LINZESS | GC-C · Constipation-related GI indications; subject to local labeling | Approved | Acts locally in the gut; systemic oral bioavailability is not the objective |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
No cataloged update explicitly mentions this company.
Ahead of the AHA meeting, an original report reviewed enlicitide analyses across PREVENT cardiovascular risk groups and an open-label extension. LDL cholesterol reductions were broadly consistent across risk categories and persisted through Week 104. The extension selected participants who had tolerated and adhered to treatment and lacked a control group, limiting generalization of its long-term findings.
Aurinia reported LUPKYNIS net product sales of $232.4 million for the nine months ended September 30, 2026, up 18%, including $79.4 million in the third quarter, up 12%. Total company revenue also includes licensing, collaboration, and royalty income. These are commercialization results for an approved oral cyclic peptide, rather than a new indication approval or clinical endpoint readout.
A new review connects peptide structure, formulation, screening, and pharmacokinetic testing in an evidence-based framework for oral drug discovery. It distinguishes architecture-led libraries, oral optimization of existing hits, and hybrid approaches. The scope includes cyclic and noncyclic peptides; the proposed framework organizes development evidence rather than demonstrating a new therapy or clinical benefit.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.
